Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
...
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
- Conditions
- Interventions
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 11016
- Registration Number
- NCT03354429
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Ottawa Heart Institute Research Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT03331484
- Locations
- 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
Add-on Cangrelor in STEMI-triggered Cardiac Arrest
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2017-09-13
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 60
- Registration Number
- NCT03273075
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Thorax Centrum Twente
- Target Recruit Count
- 2062
- Registration Number
- NCT03197298
- Locations
- 🇳🇱
Medisch Spectrum Twente, Enschede, Netherlands
Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 80
- Registration Number
- NCT03182855
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
CES1 Crossover Trial of Clopidogrel and Ticagrelor
- Conditions
- Interventions
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 111
- Registration Number
- NCT03161678
- Locations
- 🇺🇸
Amish Research Clinic, Lancaster, Pennsylvania, United States
Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD
- Conditions
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2018-05-25
- Lead Sponsor
- North Texas Veterans Healthcare System
- Target Recruit Count
- 220
- Registration Number
- NCT03150667
- Locations
- 🇺🇸
Durham VA Medical Center, Durham, North Carolina, United States
🇺🇸VA North Texas Health Care System, Dallas, Texas, United States
TIMES: Ticagrelor vs. Placebo/ Clopidogrel With Aspirin in Anterior STEMI Patients Treated With Primary PCI
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Papworth Hospital NHS Foundation Trust
- Target Recruit Count
- 140
- Registration Number
- NCT03145194
- Locations
- 🇬🇧
Papworth Hospital NHS Foundation Trust, Papworth Everard, Cambridge, United Kingdom
ADHerence of ticagrelOr in Real World Patients With aCute Coronary Syndrome
- Conditions
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2023-01-12
- Target Recruit Count
- 480
- Registration Number
- NCT03129867
P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold
- Conditions
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT03119012
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.